))
From Promise to Practice – AI's Impact on Cell and Gene Therapy Development
Manage episode 463345705 series 2994360
Content provided by [email protected] and TTP plc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by [email protected] and TTP plc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this episode, Stuart explores the adoption of generative AI in the pharmaceutical industry, with a special focus on cell and gene therapy. While the application of AI for drug discovery has been well documented and a source of considerable investment for the pharmaceutical sector, we are only just starting to see its impact for therapy developers. A 2024 report from McKinsey Global Institute estimates that generative AI could generate up to $100 billion in economic value for pharma and medical product companies, and therapy developers are eager to see these benefits sooner rather than later, no more so than in the complex and challenging field of cell and gene therapies. With the help of two expert guests, Stuart will uncover how AI is being used in the industry today, and where it could go in the future.
Guests:
- Ken Harris, Chief Strategy Officer and Head of AI at OmniaBio
- Sean Bedingfield, PhD, Senior Advisor at Eli Lilly Genetic Medicine
26 episodes
Share
